Vericel Corp

VCEL
About the company

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America.

Country: United StatesPrice: $56.96Market Cap: $2.9B

Investment snapshot

18%positive consensus
Scored 1d ago

Positive

3

BUY / PASS

Neutral / negative

1 / 12

NEUTRAL / FAIL

Median fair value

$6.58

-88.4% vs price

Models with upside

0 / 17

Positive margin of safety

Strongest signal

10 of 12 pass — Graham and Lynch object

Key risk

No clean pass — all 13 investors flag at least one valuation criterion

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILFAIL · Rank #1762 (Top 56.9%)BUYFAILFAILFAILFAILFAILPASSPASSFAILFAILFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of Safety-703.4%-1406.9%-612.0%-12019.1%N/A-2431.6%-541.4%-836.8%N/AN/A-226.0%N/AN/AN/AN/AN/AN/A
Financial Basis

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Annual history · FY 2025

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-09-30 · TTM ended 2026-09-30 vs 2025-09-30 · TTM ended 2026-09-30

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-02-26

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-02-26

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-02-26

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment · TTM ended 2026-09-30 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Qualitative assessment

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-02-26

Score computed: 2026-11-14

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-05

Score computed: 2026-11-14

TTM ended 2026-09-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Where It Passes

  • Debt & Leverage83% pass✓ 13✗ 2▾

    10 of 12 pass — Graham and Lynch object

    LT Debt vs Net Current Assets
    ✗GrahamLT Debt <= Net Current Assets
    Debt/Equity & Interest CoverageD/E: 0.00, IC: 42.0x
    ✓BuffettD/E < 0.5 AND Interest Coverage > 5x
    Total Debt / Equity0
    ✓Lynch< 0.33
    Cash - Long-term Debt
    ✗LynchPositive preferred
    LT Debt / Total Assets Change0.00% -> 0.00%
    ✓PiotroskiDecreased YoY
    Current Assets / Current Liabilities5.13
    ✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)
    Total Debt / Shareholders' Equity0
    ✓Dreman< 0.8✓Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✓SchlossD/E < 1.00x
    Debt Levels0
    ✓MungerDebt/Equity < 0.5✓AkreDebt/Equity < 0.3
    Interest Coverage & Debt/EBITDAIC=42.0x, D/EBITDA=0.0x
    ✓MarksInterest Coverage > 3x; Debt/EBITDA < 4x
    Total Debt / Shareholders Equity0
    ✓Ackman<= 1.0
    Negative debt-to-equity (higher means less debt)-0.0015; #392/4210 (top 9.3%)
    ✓AsnessTop 30% of eligible cross-section

Where It Falls Short

  • Valuation0% pass✓ 2✗ 26▾

    No clean pass — all 13 investors flag at least one valuation criterion

    Price / 3-yr avg EPS379.7x
    ✗Graham<= 15x
    Price-to-Book Ratio8.2x
    ✗Graham<= 1.5x
    P/E x P/B3,096.1
    ✗Graham<= 22.5
    Basic earnings-growth PEG (dividends excluded)4.48
    ✗Lynch< 1.0 (ideally < 0.5)
    EBIT / Enterprise Value0.4%
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=0.4%, ROC=5.3%
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Price / EPS178.0x
    ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
    Price / (CFO / Shares)55.7x
    ✗Dreman< 8x
    Price / Book Value per Share8.2x
    ✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)
    Valuation ReasonablenessP/E=178.0x, OE Yield=0.0%
    ✗MungerP/E < 25 or Owner Earnings Yield > 5%
    P/E or FCF YieldP/E=178.0x, FCF Yield=0.9%
    ✗PabraiP/E < 15 or FCF Yield > 10%
    P/B or P/E vs. Historical AverageP/E=178.0x, P/B=8.2x
    ✗MarksP/E < 15 or P/B < 2.0
    Discount to Intrinsic Value-2431.6% (IV=$2.25 vs Price=$56.96)
    ✗Marks>= 20% below intrinsic value
    Price / FCF per Share116.8x
    ✗Ackman<= 25
    Price vs. Trailing Low181% of trailing low ($31.47)
    ✗Templeton<= 120% of trailing low (certified split-adjusted live window)
    Net income / market capitalization+1.15%; #2945/6340 (top 46.5%)
    ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
    Positive book equity / market capitalization+0.1322; #4573/6449 (top 70.9%)
    ✗AsnessTop 30% of eligible cross-section
    Price / Diluted EPS178.0x
    ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
    (EPS CAGR % + Dividend Yield %) / P/E
    ✗Neff> 0.7 (Neff's published traditional edge)
    Price / Tangible Book Value per Share8.28x
    ✗SchlossP/TBV <= 1.00x (app cutoff)
    Book Value per Share Change+139.1%
    ✓SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
    Revenue / market capitalization+0.1115; #4272/5247 (top 81.4%)
    ✗OshaughnessyTop 10% of eligible cross-section
    (Operating cash flow - capex) / market capitalization+1.99%; #2254/4519 (top 49.9%)
    ✗OshaughnessyTop 10% of eligible cross-section
    Trailing six-month price return through the evaluation date+64.01%; #530/6202 (top 8.5%)
    ✓OshaughnessyTop 10% of eligible cross-section
  • Valuation models0% pass✗ 8▾

    VCEL overvalued: all 8 models price fair value below $56.96 (median $6.58)

    Graham fair value$7.09
    ✗Graham-703.4% margin vs $56.96
    Buffett fair value$3.78
    ✗Buffett-1406.9% margin vs $56.96
    Lynch fair value$8.00
    ✗Lynch-612.0% margin vs $56.96
    Greenblatt fair value$0.47
    ✗Greenblatt-12019.1% margin vs $56.96
    Dreman fair value$2.25
    ✗Dreman-2431.6% margin vs $56.96
    Munger fair value$8.88
    ✗Munger-541.4% margin vs $56.96
    Pabrai fair value$6.08
    ✗Pabrai-836.8% margin vs $56.96
    Ackman fair value$17.47
    ✗Ackman-226.0% margin vs $56.96
  • Profitability13% pass✓ 10✗ 25▾

    14 of 16 flag VCEL's profitability — Graham, Buffett, Lynch +11 more

    Positive EPS (10 years)3/26 years positive
    ✗GrahamPositive EPS every year for 10 years
    EPS Growth (3-yr avg, 10-yr window)
    ✗Graham>= 33% growth
    Net Income Positive (10+ years)3/26 years positive
    ✗BuffettPositive every year for 10+ years
    ROE (up to 5-year arithmetic mean)-1.3%
    ✗Buffett> 15% arithmetic mean (app rule)
    Operating Margin (10-yr trend)4.0% (latest)
    ✓BuffettStable or rising over 10 years
    Free Cash Flow Proxy$16.2M
    ✓BuffettPositive and growing
    Earnings Variance (10-yr CoV)
    ✗BuffettCoV < 0.3
    Retained Earnings Effectiveness
    ✗Buffett$1 retained -> > $1 market value created
    Basic earnings-growth PEG (dividends excluded)4.48
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR39.8%
    ✓Lynch15-30% (Fast Grower); > 0% to pass
    ROE8.7%
    ✗Lynch> 15%
    EBIT / Enterprise Value0.4%
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=0.4%, ROC=5.3%
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Net Income / Total Assets3.39%
    ✓PiotroskiROA > 0
    ROA Change YoY2.39% -> 3.39% (delta: +0.99%)
    ✓PiotroskiCurrent ROA > Prior ROA
    (CFO / Total Assets) vs ROACFO/Assets=10.64%, ROA=3.39%
    ✓PiotroskiCFO/Assets > ROA
    Gross Margin Change YoY72.6% -> 74.4%
    ✓PiotroskiImproved YoY
    Pre-Tax Income / Revenue6.3%
    ✗Dreman>= 8%
    Net Income / Shareholders' Equity8.7%
    ✗Dreman> 12%
    Margin of SafetyP/E=178.0x, P/B=8.2x
    ✗PabraiP/B < 1.5 or P/E < 15
    Return on Equity2.3% (3-yr avg)
    ✗AkreROE > 20% (3-year avg)
    Discount to Intrinsic Value-2431.6% (IV=$2.25 vs Price=$56.96)
    ✗Marks>= 20% below intrinsic value
    Positive Net Income Frequency3/17 years positive
    ✗MarksPositive net income in >= 7 of last 10 years
    Operating Income / Revenue8.3%
    ✗Ackman>= 15%
    Net Income / Shareholders Equity8.7%
    ✗Ackman>= 15%
    5-Year EPS CAGR39.8% CAGR over 5 years
    ✓Templeton> 0% (5-year EPS CAGR)
    Operating Margin Trend-3.3% (2023) -> 4.0% (2025)
    ✓TempletonNon-negative operating-margin trend over 3 years
    Revenue growth vs. gross and operating margin trendgross margin 68.6% -> 74.4%, operating margin -3.3% -> 4.0%
    ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
    Net income / market capitalization+1.15%; #2945/6340 (top 46.5%)
    ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
    Gross profit / total assets+46.68%; #747/3702 (top 20.2%)
    ✓AsnessTop 30% of eligible cross-section
    Net income / positive book equity+8.67%; #2009/5226 (top 38.4%)
    ✗AsnessTop 30% of eligible cross-section
    Negative 5-year standard deviation of ROA-0.0350; #2105/5884 (top 35.8%)
    ✗AsnessTop 30% of eligible cross-section
    3-5 Year Diluted EPS CAGR39.8% over 5 years
    ✗Neff7%-20% annualized
    Positive Diluted-EPS Years3/10 years positive
    ✗Schloss>= 70% positive over 5-10 observed years (app rule)
  • Verdicts19% pass✓ 3✗ 13▾

    Split decision: 12 FAIL · 2 PASS · 1 BUY · 1 NEUTRAL

    Overall verdict
    ✗GrahamFAIL (2/9)✗BuffettFAIL (3/9)✗LynchFAIL (4/7)✗GreenblattRank #1762✓PiotroskiBUY (F-Score 8)✗DremanFAIL (4/11)✗MungerFAIL (1/4)✗PabraiFAIL (0/3)✗AkreFAIL (2/6)✗MarksFAIL (1/5)✓AckmanPASS (5/9)✓TempletonPASS (4/8)✗SleepFAIL (1/6)✗AsnessFAIL (Rank #993/2370 (Top 41.9%))✗NeffFAIL (2/6)✗SchlossFAIL (3/7)•OshaughnessyNEUTRAL (Not ranked)
  • Growth25% pass✓ 7✗ 6▾

    6 of 8 flag VCEL's growth — Graham, Lynch, Dreman +3 more

    EPS Growth (3-yr avg, 10-yr window)
    ✗Graham>= 33% growth
    Basic earnings-growth PEG (dividends excluded)4.48
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR39.8%
    ✓Lynch15-30% (Fast Grower); > 0% to pass
    Inventory Growth vs Revenue GrowthInv: -6.1% vs Rev: 25.3%
    ✓LynchInventory growth < Revenue growth
    EPS Growth Direction
    ✗DremanPositive over recent years
    EPS CAGR39.8% CAGR over 5 years
    ✓Dreman> 5% annualized
    Positive Net Income Frequency3/17 years positive
    ✗MarksPositive net income in >= 7 of last 10 years
    3yr Median Revenue Growth20.1%
    ✓Ackman>= 5%
    Positive EPS Growth Frequency3/5 years with positive EPS growth
    ✓AckmanPositive EPS growth in >= 3 of last 5 years
    5-Year EPS CAGR39.8% CAGR over 5 years
    ✓Templeton> 0% (5-year EPS CAGR)
    Revenue growth vs. gross and operating margin trendgross margin 68.6% -> 74.4%, operating margin -3.3% -> 4.0%
    ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
    5-year Revenue CAGR17.3%
    ✓SleepCAGR > 7%
    3-5 Year Diluted EPS CAGR39.8% over 5 years
    ✗Neff7%-20% annualized
  • Efficiency38% pass✓ 4✗ 7▾

    5 of 8 flag VCEL's efficiency — Buffett, Greenblatt, Munger +2 more

    Current Ratio5.13
    ✓Graham>= 2.0
    ROIC (3-5 yr avg)-2.8%
    ✗Buffett> 10%
    ROIC - WACC-12.8%
    ✗BuffettPositive (WACC = 10%)
    EBIT / (NWC + Net Fixed Assets)5.3%
    ✗Greenblatt> 25%
    Current Ratio Change YoY4.23 -> 5.03
    ✓PiotroskiIncreased YoY
    Revenue / Total Assets Change YoY0.55x -> 0.57x
    ✓PiotroskiImproved YoY
    Current Assets / Current Liabilities5.13
    ✓Dreman> 1.5
    Return on Invested Capital5.5%
    ✗Munger> 15%
    ROIC (high and growing)FY2023: ROIC=-2.3%; FY2024: ROIC=1.2%; FY2025: ROIC=2.5%
    ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
    Reinvestment Rate x ROIC2.5% (RR=100% x ROIC=2.5%)
    ✗AkreReinvestment Rate * ROIC > 10%
    ROIC (5-year)0/5 years above 12% (latest 2.5%)
    ✗SleepROIC > 12% in a majority of years
  • Cash Flow40% pass✓ 5✗ 7▾

    6 of 10 flag VCEL's cash flow — Dreman, Pabrai, Marks +3 more

    Free Cash Flow Proxy$16.2M
    ✓BuffettPositive and growing
    FCF Positive and Growing$57.9M
    ✓LynchPositive and growing
    Operating Cash Flow$51.9M
    ✓PiotroskiCFO > 0
    (CFO / Total Assets) vs ROACFO/Assets=10.64%, ROA=3.39%
    ✓PiotroskiCFO/Assets > ROA
    Price / (CFO / Shares)55.7x
    ✗Dreman< 8x
    P/E or FCF YieldP/E=178.0x, FCF Yield=0.9%
    ✗PabraiP/E < 15 or FCF Yield > 10%
    FCF Positive5/17 years FCF positive
    ✗MarksPositive FCF in majority of recent years
    (OCF - CapEx) / Market Cap2.0%
    ✗Ackman>= 4%
    Price / FCF per Share116.8x
    ✗Ackman<= 25
    Positive Operating Cash Flow frequency6/17 years positive
    ✗SleepPositive OCF in >= 70% of available years
    Operating Cash Flow - Capital Expenditures$57.9M
    ✓Neff> $0 (app proxy for a strong fundamental case)
    (Operating cash flow - capex) / market capitalization+1.99%; #2254/4519 (top 49.9%)
    ✗OshaughnessyTop 10% of eligible cross-section

Business & financials

Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

Company Profile

Industry: Pharmaceutical Products
SIC Sector: Chemicals & Pharmaceuticals
Size: Mid Cap($2.9B)
Revenue: $276.3M+16.5% YoY
Net Income: $16.5M+59.4% YoY

Financial Snapshot

Operating Margin4.0%
Return on Equity4.7%
Debt / Equity0.00
Current Ratio5.03
EPS (Diluted)$0.32+60.0% 1y
Shares Retired−1.6% / −5.1% 2y

Similar Companies

MRKMerck & Co., Inc.
$364.3B
ABTABBOTT LABORATORIES
$188.0B
BMYBRISTOL MYERS SQUIBB CO
$129.7B
TECHBIO-TECHNE Corp
$11.4B

Shareholder Return

Fiscal 2025

Issued 1.6% of shares last year, 5.1% issued over two.

Buybacks
—
Dividends
—

What drove EPS

A buyback raises earnings per share without the company earning more. This splits each year's change into the two.

FY25
60.0% = 59.4% + 0.4%
Earnings Fewer shares More shares

Share count is the denominator the filer used for diluted EPS, recovered as net income ÷ EPS — not the balance-sheet count, which is a point-in-time figure and would put the timing difference into this split. Years with a loss are omitted: a smaller share count makes a loss per share larger, so the decomposition inverts.

Company Financials

Latest TTM and quarters alongside annual years

TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

MetricTTM · 2026-09-30

2025-10-01 – 2026-09-30

Sources · derived quarter values

Derived from cumulative filings: revenue, net income, operating income, gross profit, ebit, interest expense, operating cash flow, depreciation amortization, capex.

Q3 FY 2026

2026-07-01 – 2026-09-30

Sources · derived quarter values

Derived from cumulative filings: operating cash flow, depreciation amortization, capex.

Q2 FY 2026

2026-04-01 – 2026-06-30

Sources · derived quarter values

Derived from cumulative filings: operating cash flow, depreciation amortization, capex.

Q1 FY 2026

2026-01-01 – 2026-03-31

Sources
FY 2025
Sources
  • 10-K · 2026-02-26
FY 2024
Sources
  • 10-K · 2025-02-27
FY 2023
Sources
  • 10-K · 2024-02-29
FY 2022
Sources
  • 10-K · 2023-02-23
FY 2021
Sources
  • 10-K · 2022-02-24
Market Cap$2.9Bcurrent------$1.8Best.$2.9Best.$2.1Best.$1.3Best.$1.7Best.
Revenue$324.2M↑25%$85.4M↑26%$77.5M↑22%$68.4M↑30%$276.3M↑16%$237.2M↑20%$197.5M↑20%$164.4M↑5%$156.2M
Operating Income$27.0M↑279%$12.2M↑253%$434.0K↑121%-$8.1M↑37%$11.0M↑144%$4.5M↑170%-$6.5M↑62%-$17.1M↓117%-$7.9M
Net Income$33.3M↑155%$14.2M↑179%$2.2M↑499%-$6.3M↑44%$16.5M↑59%$10.4M↑426%-$3.2M↑81%-$16.7M↓124%-$7.5M
EPS (Diluted)--$0.27↑170%$0.04↑500%$-0.12↑48%$0.32↑60%$0.20↑386%$-0.07↑80%$-0.35↓119%$-0.16
Gross Margin74.5%↑1%73.3%72.8%↓1%72.0%↑4%74.4%↑3%72.6%↑6%68.6%↑3%66.8%↓2%67.9%
Operating Margin8.3%↑203%14.3%↑179%0.6%↑117%-11.8%↑52%4.0%↑110%1.9%↑158%-3.3%↑68%-10.4%↓106%-5.0%
ROE8.7%↑113%———4.7%↑31%3.5%↑352%-1.4%↑84%-8.7%↓98%-4.4%
Total Debt$574.0K↓13%$574.0K↓13%$596.0K↓11%$617.0K↓10%$638.0K↓7%$686.0K$0↓100%$41.0K↓52%$85.0K
Shareholders' Equity$384.2M↑19%$384.2M↑19%$370.0M↑21%$356.2M↑21%$354.6M↑21%$292.0M↑29%$226.0M↑18%$192.3M↑13%$170.5M
Current Ratio5.13↑5%5.13↑5%5.04↑1%5.18↑3%5.03↑19%4.23↓6%4.49↓10%4.99↓18%6.08
Debt / Equity0.00↓27%0.00↓27%0.00↓26%0.00↓25%0.00↓23%0.000.00↓100%0.00↓57%0.00
Operating Cash Flow$65.3M↑10%$17.7M↓20%$16.2M↑97%$16.4M↑148%$51.9M↓11%$58.2M↑65%$35.3M↑100%$17.7M↓39%$29.0M
Free Cash Flow$57.9M↑184%$15.7M↓19%$14.3M↑17504%$15.1M↑299%$24.7M↑526%-$5.8M↓138%$15.3M↑52%$10.1M↓52%$21.1M

Score history

Historical Score Timeline

Industry peers

Industry Peers

Similar companies in Pharmaceutical Products

VCEL vs Peers — Financial Grading

Revenue$276.3MBottom 25%
Net Income$16.5MMedian
ROE4.7%Median
D/E0.00Top 25%
Op. Margin4.0%Median
Curr. Ratio5.03Top 25%
CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
Merck & Co., Inc.MRK$364.3B$147.76$65.0B$18.3B34.7%0.94—1.542/95/94/70/3F-Score 41/11
ABBOTT LABORATORIESABT$188.0B$108.52$44.3B$6.5B12.5%0.2518.2%1.583/94/92/71/3F-Score 53/11
BRISTOL MYERS SQUIBB COBMY$129.7B$63.43$48.2B$7.1B38.2%2.4419.4%1.262/91/93/71/3F-Score 85/11
BIO-TECHNE CorpTECH$11.4B$72.80$1.2B$73.4M3.8%—8.4%3.464/93/93/70/3F-Score 54/11
REPLIGEN CORPRGEN$10.7B$167.79$738.3M$48.9M2.3%0.267.5%8.373/92/93/70/3F-Score 75/11
IONIS PHARMACEUTICALS INCIONS$4.8B$29.06$943.7M$381.4M-78.0%3.60-40.4%3.833/91/91/70/3F-Score 43/11
NEOGEN CORPNEOG$2.5B$11.23$870.4M$7.9M-0.4%0.76-2.5%3.823/91/92/70/3F-Score 64/11
Pharvaris N.V.PHVS$2.4B$33.36—$206.4M-64.8%0.00——0/90/92/70/3F-Score 22/11